Xiangyu Medical(SH:688626)2025-10-30 13:35Financial Performance - The company's operating revenue for the third quarter was ¥177,983,291.97, an increase of 5.46% compared to the same period last year[4]. - The total profit for the quarter decreased by 71.05% to ¥5,236,453.20, while the net profit attributable to shareholders fell by 48.82% to ¥8,586,869.79[4][8]. - The basic earnings per share for the quarter was ¥0.06, down 45.45% from the same period last year[4][8]. - The company's total profit for the year-to-date period decreased by 44.06% to ¥44,305,425.87[4][8]. - Net profit for the first three quarters of 2025 was ¥41,907,442.75, a decrease of 43% from ¥73,382,295.90 in the previous year[22]. - Basic earnings per share for the period was ¥0.29, down from ¥0.47 in the same period last year[23]. Research and Development - Research and development expenses amounted to ¥49,094,672.85, representing 27.58% of operating revenue, an increase of 4.80 percentage points year-on-year[5]. - Research and development expenses rose to ¥125,479,123.87, an increase of 20.5% compared to ¥104,122,259.04 in 2024[21]. - The company achieved a total of 387 medical device registration certificates and filings, with 10 new additions during the reporting period[12]. - The company obtained 87 new patents, including 30 invention patents, bringing the total to 1,936 patents[12]. - The company has accumulated 2,340 intellectual property rights, including 1,070 utility model patents[14]. Assets and Liabilities - The total assets of the company increased by 11.76% to ¥3,272,197,143.87 compared to the end of the previous year[5]. - Total assets increased to ¥3,272,197,143.87, compared to ¥2,927,874,338.81 at the end of the previous year[19]. - Total liabilities rose to ¥1,231,446,217.25, up from ¥873,096,802.37 year-over-year[19]. - The company's equity attributable to shareholders decreased to ¥2,026,726,626.27 from ¥2,038,679,134.12 in the previous year[19]. Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥71,197,504.58, a decrease of 23.43% compared to the previous year[4]. - Cash inflow from operating activities for the first three quarters of 2025 was $693.38 million, an increase of 8.8% compared to $637.26 million in the same period of 2024[25]. - Net cash flow from operating activities decreased to $71.20 million in 2025 from $92.98 million in 2024, reflecting a decline of 23.5%[25]. - Total cash inflow from investment activities was $106.16 million in 2025, significantly lower than $324.26 million in 2024, marking a decrease of 67.2%[26]. - Net cash flow from investment activities was -$295.11 million in 2025, worsening from -$186.98 million in 2024[26]. - Cash inflow from financing activities increased to $818.50 million in 2025, compared to $492.00 million in 2024, representing a growth of 66.3%[26]. - Net cash flow from financing activities was $255.14 million in 2025, up from $151.23 million in 2024, indicating a rise of 68.7%[26]. - The ending cash and cash equivalents balance for 2025 was $734.13 million, compared to $709.13 million in 2024, showing an increase of 3.5%[26]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 9,531[10]. - The largest shareholder, Henan Xiangyu Health Industry Management Co., Ltd., holds 56.43% of the shares[10]. - The company has a total of 90,286,560 shares held by Henan Xiangyu Health Industry Management Co., Ltd., representing a significant shareholder[11]. Achievements and Recognition - The company successfully led a major scientific project in Henan Province focused on key technologies for traditional Chinese medicine therapy robots[12]. - The company was awarded the third prize in military scientific and technological progress[13]. - The company has been recognized as a member of the Brain-Computer Interface Technology Innovation and Industry Service Alliance[13]. - The company’s intelligent workshop for rehabilitation medical devices was rated as a smart workshop in Henan Province for 2025[13].